Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sara A. Hurvitz, Miguel Martin, William Fraser Symmans, Kyung Hae Jung, Chiun-Sheng Huang, Alastair Mark Thompson, Nadia Harbeck, Vicente Valero, Daniil Stroyakovskiy, Hans Wildiers, Karen Afenjar, Rodrigo Fresco, Hans-Joachim Helms, Jin Xu, Yvonne Gail Lin, Joseph A. Sparano, Dennis J. Slamon
Institutions: University of California, Los Angeles, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, The University of Texas MD Anderson Cancer Center, Asan Medical Center, University of Ulsan, National Taiwan University Hospital, Ludwig-Maximilians-Universität München, Moscow City Oncology Hospital №62, Universitair Ziekenhuis Leuven, Translational Research in Oncology, F. Hoffmann-La Roche AG, Genentech, Albert Einstein College of Medicine, Montefiore Medical Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2724318580